The purpose of the study was to compare the clinical efficacy of breast conserving surgery and modified radical mastectomy in the treatment of early breast cancer.Firstly,the clinical data of 74 patients with early br...The purpose of the study was to compare the clinical efficacy of breast conserving surgery and modified radical mastectomy in the treatment of early breast cancer.Firstly,the clinical data of 74 patients with early breast cancer treated in our hospital from June 2015 to June 2016 were retrospectively analyzed.Among them,37 patients treated with breast-conserving surgery were set as the study group,and 37 patients treated with modified radical surgery were set as the control group,and the therapeutic effects of the two groups were compared.The results showed that compared with the control group,the incision length,intraoperative blood loss,operation time and hospital stay time were better in the study group,and the excellent and good rate of postoperative breast beauty was higher,with statistically significant differences(P<0.05).There were no statistically significant differences in distant metastasis rate,local recurrence rate,axillary lymph node recurrence rate and fatality rate between the two groups(P>0.05).Therefore,breast-conserving surgery and modified radical surgery have better efficacy in the treatment of early breast cancer,but breast-conserving surgery has more advantages,such as smaller incision,less intraoperative blood loss,shorter operative time and hospital stay,and better postoperative aesthetic effect,which can be used as the first choice for early breast cancer.展开更多
目的系统评价中医药联合化疗治疗大肠癌根治术后患者的临床效果。方法计算机检索1995年1月~2015年12月中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)、万方科技期刊全文数据库(Web版)、中文科技期刊数据库(VIP)、Pub Med、ISI...目的系统评价中医药联合化疗治疗大肠癌根治术后患者的临床效果。方法计算机检索1995年1月~2015年12月中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)、万方科技期刊全文数据库(Web版)、中文科技期刊数据库(VIP)、Pub Med、ISI Web of Knowledge、Cochrane Library医学数据库以及中国重要会议论文全文数据库。根据纳入、排除标准来确定入选文献后,参考Cochrane手册提供的质量评价标准对符合纳入标准的文献进行质量评价,应用Rev Man 5.3软件进行统计分析。结果本研究共纳入文献12篇,结果显示中医药联合化疗可改善大肠癌根治术患者的生活质量(QOL)(RR=1.76,95%CI:1.35~2.30,P<0.0001),提高5年生存率(RR=1.72,95%CI:1.18~2.49,P=0.005),升高CD3^+、CD4^+细胞计数和CD4^+/CD8^+比值(MD=18.95,95%CI:0.09~37.82,P<0.05;MD=5.87,95%CI:2.25~9.49,P=0.00;MD=0.24,95%CI:0.11~0.38,P=0.00),降低胃肠道毒副作用发生率(RR=0.51,95%CI:0.42~0.61,P<0.000 01),增高化疗后白细胞水平(RR=0.51,95%CI:0.31~0.83,P=0.007)。结论中医药联合化疗可提高大肠癌根治术后患者的远期疗效,减轻化疗毒副作用,改善生活质量,提高机体免疫力。展开更多
文摘The purpose of the study was to compare the clinical efficacy of breast conserving surgery and modified radical mastectomy in the treatment of early breast cancer.Firstly,the clinical data of 74 patients with early breast cancer treated in our hospital from June 2015 to June 2016 were retrospectively analyzed.Among them,37 patients treated with breast-conserving surgery were set as the study group,and 37 patients treated with modified radical surgery were set as the control group,and the therapeutic effects of the two groups were compared.The results showed that compared with the control group,the incision length,intraoperative blood loss,operation time and hospital stay time were better in the study group,and the excellent and good rate of postoperative breast beauty was higher,with statistically significant differences(P<0.05).There were no statistically significant differences in distant metastasis rate,local recurrence rate,axillary lymph node recurrence rate and fatality rate between the two groups(P>0.05).Therefore,breast-conserving surgery and modified radical surgery have better efficacy in the treatment of early breast cancer,but breast-conserving surgery has more advantages,such as smaller incision,less intraoperative blood loss,shorter operative time and hospital stay,and better postoperative aesthetic effect,which can be used as the first choice for early breast cancer.
文摘目的系统评价中医药联合化疗治疗大肠癌根治术后患者的临床效果。方法计算机检索1995年1月~2015年12月中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)、万方科技期刊全文数据库(Web版)、中文科技期刊数据库(VIP)、Pub Med、ISI Web of Knowledge、Cochrane Library医学数据库以及中国重要会议论文全文数据库。根据纳入、排除标准来确定入选文献后,参考Cochrane手册提供的质量评价标准对符合纳入标准的文献进行质量评价,应用Rev Man 5.3软件进行统计分析。结果本研究共纳入文献12篇,结果显示中医药联合化疗可改善大肠癌根治术患者的生活质量(QOL)(RR=1.76,95%CI:1.35~2.30,P<0.0001),提高5年生存率(RR=1.72,95%CI:1.18~2.49,P=0.005),升高CD3^+、CD4^+细胞计数和CD4^+/CD8^+比值(MD=18.95,95%CI:0.09~37.82,P<0.05;MD=5.87,95%CI:2.25~9.49,P=0.00;MD=0.24,95%CI:0.11~0.38,P=0.00),降低胃肠道毒副作用发生率(RR=0.51,95%CI:0.42~0.61,P<0.000 01),增高化疗后白细胞水平(RR=0.51,95%CI:0.31~0.83,P=0.007)。结论中医药联合化疗可提高大肠癌根治术后患者的远期疗效,减轻化疗毒副作用,改善生活质量,提高机体免疫力。
